1. Home
  2. OST vs MEIP Comparison

OST vs MEIP Comparison

Compare OST & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OST
  • MEIP
  • Stock Information
  • Founded
  • OST 2010
  • MEIP 2000
  • Country
  • OST China
  • MEIP United States
  • Employees
  • OST N/A
  • MEIP N/A
  • Industry
  • OST Industrial Machinery/Components
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • OST Technology
  • MEIP Health Care
  • Exchange
  • OST Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • OST 15.7M
  • MEIP 13.3M
  • IPO Year
  • OST 2022
  • MEIP 2003
  • Fundamental
  • Price
  • OST $0.10
  • MEIP $5.95
  • Analyst Decision
  • OST
  • MEIP Hold
  • Analyst Count
  • OST 0
  • MEIP 1
  • Target Price
  • OST N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • OST 36.1M
  • MEIP 2.9M
  • Earning Date
  • OST 08-25-2025
  • MEIP 09-18-2025
  • Dividend Yield
  • OST N/A
  • MEIP N/A
  • EPS Growth
  • OST N/A
  • MEIP N/A
  • EPS
  • OST N/A
  • MEIP N/A
  • Revenue
  • OST $38,333,251.00
  • MEIP N/A
  • Revenue This Year
  • OST N/A
  • MEIP N/A
  • Revenue Next Year
  • OST N/A
  • MEIP N/A
  • P/E Ratio
  • OST N/A
  • MEIP N/A
  • Revenue Growth
  • OST 0.34
  • MEIP 33.76
  • 52 Week Low
  • OST $0.10
  • MEIP $1.46
  • 52 Week High
  • OST $9.40
  • MEIP $9.00
  • Technical
  • Relative Strength Index (RSI)
  • OST 25.01
  • MEIP 68.88
  • Support Level
  • OST $0.10
  • MEIP $5.75
  • Resistance Level
  • OST $0.13
  • MEIP $6.91
  • Average True Range (ATR)
  • OST 0.01
  • MEIP 0.94
  • MACD
  • OST 0.17
  • MEIP 0.27
  • Stochastic Oscillator
  • OST 7.00
  • MEIP 52.04

About OST Ostin Technology Group Co. Ltd.

Ostin Technology Group Co Ltd is a supplier of display modules and polarizers in China. It designs, develops, and manufactures TFT-LCD modules in a wide range of sizes and customized sizes according to the specifications of its customers. Its display modules are mainly used in consumer electronics, commercial LCD displays, and automotive displays. The company also manufactures polarizers used in the TFT-LCD display modules and is in the process of developing polarizers for the OLED display panel. Geographically, the company generates revenue from Hong Kong, Taiwan, and Mainland China which is its key revenue generating market.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: